Prevalence of Sarcopenia Among Elderly Living in Care Facilities in Klang Valley, Malaysia

April 2, 2019 updated by: Pramod Divakara Shenoy, MPT, Universiti Tunku Abdul Rahman

A Preliminary Study of Prevalence of Sarcopenia Among Elderly Living in Care Facilities in Klang Valley, Malaysia

The primary aim of this study was to investigate the prevalence of age-related progressive decline in muscle mass and strength (Sarcopenia) among Malaysian elderly residing in long-term care facilities. It is a very important condition to study as it is associated with high incidence of fall, hospitalization and mortality.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Over the past few decades, one condition that prominently affects the muscular system, known as sarcopenia, has captured the attention of healthcare experts and researchers. Sarcopenia is a geriatric syndrome characterized by the involuntary, gradual and generalized deterioration of skeletal muscle mass and strength with advancing age. It is to be noted that while sarcopenia is predominantly a syndrome of the elderly, its development may also be observed in various conditions such as disuse, malnutrition and cachexia, all of which are not exclusive only to the elderly. As of now, there are still ongoing research on an international scale with regards to its epidemiology, risk factors, causative factors, adverse clinical complications, prevention and treatment.

Beginning in 1st of October, 2016, Centres for Disease Control and Prevention (CDC) has finally officialised an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10- CM) code for sarcopenia after its final proposal since April 2015. This establishment has enabled comprehensible clinical guidelines for diagnosis and treatment of sarcopenia, as well as separate reporting and data collection for sarcopenia in the medical community.

In essence, sarcopenia appears to be one of the most important causes of functional impairment, physical disability and loss of independence in older adults and a prevalence study will help to estimate the deleterious effects of this condition on the elderly living in the care facility, who happen to be the less privileged group as compared to their counterparts dwelling in the community.

Study Type

Observational

Enrollment (Actual)

205

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

58 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Elderly living in long-term care facilities (Institutionalized elderly) in Klang valley. Only Seven facilities allowing access to the study subjects were studied

Description

Inclusion Criteria:

  • Currently residing in a long-term care facility
  • Ability to walk, with or without the use of any walking aid
  • Citizen of Malaysia

Exclusion Criteria:

  • Inability to stand for height, weight and gait speed assessments
  • Presence of cardiac pacemaker
  • Presence of artificial limbs / prosthesis / metal implants
  • Difficult or dangerous behaviours
  • Severe cardiac, pulmonary, or musculoskeletal disorders
  • Severe cognitive impairment or any disability that makes communication impossible
  • Presence of terminal illness
  • Co-morbidities associated with high risk of falls (e.g. Parkinson's disease or CVA) or that may directly influence affect gait speed

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Ecologic or Community
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Skeletal muscle mass
Time Frame: 10 minutes
The skeletal muscle mass was measured using a Research grade Segmental BioImpedance Analyser to help derive the skeletal muscle mass index (Appendicular skeletal muscle mass/square of height= kg/m2)
10 minutes
Grip strength
Time Frame: 1 minute to 10 minutes
Measurement of muscle strength was done using a Jamar hydraulic handheld dynamometer, only one maximal effort was allowed. However, for erroneous performance another attempt was provided after 10 minutes of rest. The measure was recorded in Kgf.
1 minute to 10 minutes
Gait speed
Time Frame: less the 10 minutes on an average
Usual gait speed was used as a measure of physical performance, where the subject was required to walk along a 5 meter straight path. Time recorded using a stopwatch and speed recorded in meters per second
less the 10 minutes on an average

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universiti Tunku Abdul Rahman

Investigators

  • Study Director: sook Fan Yap, FRCP (UK), Universiti Tunku Abdul Rahman

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 6, 2016

Primary Completion (Actual)

December 4, 2017

Study Completion (Actual)

December 4, 2017

Study Registration Dates

First Submitted

April 2, 2019

First Submitted That Met QC Criteria

April 2, 2019

First Posted (Actual)

April 4, 2019

Study Record Updates

Last Update Posted (Actual)

April 4, 2019

Last Update Submitted That Met QC Criteria

April 2, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • U/SERC/77/2016

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

Clinical Trials on Sarcopenia assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe